Myriad Genetics (MYGN) 2024 Wells Fargo Healthcare Conference summary

Transformation and business evolution

• Four-year transformation under current leadership has shifted focus to profitable growth across three business lines: women's health, oncology, and pharmacogenomics.

• Achieved double-digit top-line growth for several quarters, with Q2 showing 15% revenue growth and profitability on Adjusted EBITDA and EPS.

• Investments in commercial effectiveness, operational automation, and technology are driving scalability and future performance.

• EMR integrations and digital investments are prioritized to enhance provider and patient experience, supporting share gains.

• Diversified revenue streams help offset risks in any single product line.

Reimbursement, ASPs, and revenue cycle management

• Revenue cycle and payer market capabilities have matured, reducing the no-pay rate from 46% to 44% and targeting further improvement.

• GeneSight, the youngest product, has the highest no-pay rate (over 60%) but is seeing incremental improvement.

• Expanded coverage is the most impactful driver for improving GeneSight reimbursement, supported by state biomarker legislation and experienced clinical staff.

• Hereditary cancer ASPs have stabilized after industry disruptions, aided by less payer pressure and improved back-office processes.

• Revenue cycle investments include automation and process enhancements to address payer requirements and reduce human error.

Growth outlook and market dynamics

• Long-term revenue growth target increased from 10% to 12%, reflecting improved ASP environment and confidence in future coverage wins.

• Hereditary cancer volume expected to grow double digits in 2025 with stable ASPs, supported by EMR integration and share shift opportunities.

• Share gains from market exits are expected to materialize more in the second half of the year, especially in hereditary cancer and prenatal.

• Upside from ACOG guideline updates in women's health could add $10–$20 million in revenue, but realization will be gradual over 6–24 months.

• Seasonality and prior period benefits will impact Q3 revenues, but overall ASP and revenue cycle health remain strong.